Abstract: Objective The aim of this study was to investigate combination of prednisolone and magnesium isoglycyrrhizinate in treatment of patients with autoimmune hepatitis(AIH). Methods 91 patients with AIH were encountered in our hospital between April 2021 and April 2024, and were randomly assigned to receive prednisolone in control (n=45), or prednisolone with combination of magnesium isoglycyrrhizinate in observation (n=46) group. The regimen lasted for 6 months. Aspartate aminotransferase (AST)/platelet ratio index (APRI) and fibrosis based on four factors (FIB-4) were obtained. Serum superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and malondialdehyde (MDA) levels were assayed by ELISA, and serum immunoglobulin IgA, IgM and IgG levels were also detected by ELISA. Liver stiffness measurement (LSM) was performed by using transient elastography. Results By end of six month treatment, serum ALT and AST levels in combination group were (46.4±5.2)U/L and (38.4±5.8)U/L, both significantly lower than [(80.8±8.0)U/L and (75.0±7.7)U/L, respectively, P<0.05] in the control; LSM, APRI and FIB-4 scores were (6.4±0.6)kPa,(1.7±0.2) and (2.8±0.3), all not significantly different as compared to [(6.4±0.6)kPa,(1.7±0.2) and (3.0±0.3), respectively, P>0.05] in the control group; serum IgA, IgM and IgG levels were(3.2±0.3)g/L, (14.3±1.5)g/L and (3.5±0.5)g/L, all significantly lower than [(4.8±0.5)g/L,(17.6±1.8)g/L and (5.0±0.6)g/L, respectively, P<0.05] in the control; serum SOD and GSH-Px levels were (83.5±8.3)U/L and (118.7±12.1)ng/L, both much higher than [(77.5±7.8)U/L and (105.6±10.2)ng/L, P<0.05], while serum MDA level was (3.3±0.3)ng/L, much lower than [(4.7±0.3)ng/L, P<0.05]in the control group. Conclusion The combination of prednisolone and magnesium isoglycyrrhizinate is a satisfactory alteration in treatment of patients with AIH, which needs further clinical observation.

Key words: Autoimmune hepatitis, Prednisolone, Magnesium isoglycyrrhizinate, Therapy